Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies.

× No keyword cloud information.

14 in total

1. Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism.

Authors: Cláudia Ribeiro; Maria Goretti Moreira Guimarães Penido; Milena Maria Moreira Guimarães; Marcelo de Sousa Tavares; Bruno das Neves Souza; Anderson Ferreira Leite; Leonardo Martins Caldeira de Deus; Lucas José de Campos Machado
Journal: World J Nephrol Date: 2016-09-06

2. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

Authors: Hirotaka Komaba; Shohei Nakanishi; Akira Fujimori; Motoko Tanaka; Jeongsoo Shin; Koji Shibuya; Masato Nishioka; Hirohito Hasegawa; Takeshi Kurosawa; Masafumi Fukagawa
Journal: Clin J Am Soc Nephrol Date: 2010-08-26 Impact factor: 8.237

Review 3. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?

Authors: James B Wetmore; L Darryl Quarles
Journal: Nat Clin Pract Nephrol Date: 2008-10-28

4. Molecular pathways associated with transcriptional alterations in hyperparathyroidism.

Authors: Fang Lee; Jie-Jen Lee; Woan-Ching Jan; Chih-Jen Wu; Han-Hsiang Chen; Shih-Ping Cheng
Journal: Oncol Lett Date: 2016-05-25 Impact factor: 2.967

5. EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.

Authors: Margit Hemetsberger; Rainer Oberbauer; Helmut Erb; Wolfgang Pronai
Journal: Wien Med Wochenschr Date: 2015-08-25

6. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.

Authors: Charles Henley; James Davis; Gerald Miller; Edward Shatzen; Russ Cattley; Xiaodong Li; David Martin; Wei Yao; Nancy Lane; Victoria Shalhoub
Journal: Eur J Pharmacol Date: 2009-05-24 Impact factor: 4.432

7. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?

Authors: Carlo Lomonte; Luigi Vernaglione; Domenico Chimienti; Andrea Bruno; Savino Cocola; Annalisa Teutonico; Francesco Cazzato; Carlo Basile
Journal: Clin J Am Soc Nephrol Date: 2008-03-05 Impact factor: 8.237

8. Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.

Authors: James B Wetmore; L Darryl Quarles
Journal: Int J Nephrol Renovasc Dis Date: 2008-11-13

9. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.

Authors: Gerald Miller; James Davis; Edward Shatzen; Matthew Colloton; David Martin; Charles M Henley
Journal: Nephrol Dial Transplant Date: 2011-10-29 Impact factor: 5.992

10. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.

Authors: Mario Meola; Ilaria Petrucci; Giuliano Barsotti
Journal: Nephrol Dial Transplant Date: 2009-01-30 Impact factor: 5.992